Merck Pharmaceutical, a global leader in healthcare and life sciences, is proud to announce the official launch of Euthyrox (levothyroxine sodium) in Nigeria.
The launch held in Lagos, marks a significant milestone in the company’s commitment to improving thyroid health and providing innovative solutions to patients in Nigeria.
Established in Germany over 356 years ago, Merck has a presence in 66 countries worldwide and is renowned for its advancements in drug formulations.
The introduction of Euthyrox, used for the treatment and prevention of thyroid disorders, underscores Merck’s dedication to enhancing patient care and addressing unmet medical needs.
This is the first time the medical product makes its way into the Nigerian market as the country joins over 100 other countries in its adoption, after receiving approval from the National Agency for Food and Drug Administration and Control (NAFDAC)
The event, attended by healthcare professionals, industry leaders, and government representatives, had a panel session where participants interacted, particularly on capacity building and possible collaborations.
Professor Salman Razvi, Consultant Endocrinologist from the UK, provided insights into the clinical benefits of Euthyrox and its impact on thyroid health through his well-thought-through presentation.
Country Manager, Merck West Africa, Charles Ajibo, emphasised the company’s dedication to addressing the unmet medical needs of patients in Nigeria.
